Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1273 in Hepatic Impairment
NCT05856513Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of anlatrelvir (3 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time zero to infinity and 2 more. Started Jun 2023; status: completed.
02
Drugs
anlatrelvir
Beyond the preview
Go deeper on NCT05856513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856513.